FDA Inspection
SPI Pharma, SASSPI Pharma, SAS – FDA Inspection, Apr 26, 2024
Record Details
This FDA Inspection record concerns SPI Pharma, SAS, with an inspection on April 26, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · d858a97a-f3ad-4dbb-8197-924c2b9cf511
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1273714
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of SPI Pharma, SAS
4| Date | Classification | Office | Project area |
|---|---|---|---|
| June 29, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 12, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 14, 2013 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 29, 2009 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for SPI Pharma, SAS
- FDA Inspection 1125749 - 2018-06-29
- FDA Inspection 968552 - 2016-02-12
- FDA Inspection 826851 - 2013-02-14
- FDA Inspection 621071 - 2009-09-29
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.